Use of anti-HER2 antibody-drug conjugate in cancer treatment
US12150944B2 · kind B2 · utility
0Cited by
0References
26Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 30, 2019 |
| Grant date | Nov 26, 2024 |
| Priority date | — |
| Expiry date | May 18, 2042 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/505
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed in the present invention is the use of an anti-HER2 antibody-drug conjugate in cancer treatment. Further provided in the present invention is the use of a pharmaceutically acceptable salt, stereoisomer, or metabolite thereof, or a solvate of each of the foregoing in the manufacture of a medicament for the prophylaxis and/or treatment of a cancer insensitive or irresponsive to a treatment with a HER2-targeting agent.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.